Clinical Trial Update: Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating leronlimab (PRO 140) in combination with carboplatin for CCR5-positive metastatic triple-negative breast cancer was terminated, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Leronlimab (PRO 140) (leronlimab)

Snippet

Sponsor: CytoDyn, Inc. | Conditions: Triple Negative Breast Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-09-09